1
|
Ge C, Yang X, Xin J, Gong X, Wang X, Kong L. Recent Advances in Antitumor Dendritic Cell Vaccines. Cancer Biother Radiopharm 2023; 38:450-457. [PMID: 37699203 DOI: 10.1089/cbr.2023.0041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/14/2023] Open
Abstract
Background: Dendritic cells (DCs) are the most important antigen-presenting cells in the body and play a key role in antigen recognition, uptake, processing, and presentation and mediate nonspecific immunity and specific immunity. Purpose: To summarize the main findings that DC vaccines are a new immunotherapy scheme combining the strengths of tumor antigens and DCs that can boost the body's identification and clearance of tumors. Methods: In this review, the authors focus on the biological characteristics of DCs, recent advances in the understanding of antitumor mechanisms, and the classification of DC vaccines. Results: The current progress of DC-based vaccine immunotherapy for common tumors with high morbidity or mortality in China were systematically summarize. Conclusions: The DC vaccines combining the strengths of tumor antigens will provide directions to explore reasonable, safe, and effective combination immunotherapy strategies for tumors in the future.
Collapse
Affiliation(s)
- Chunxia Ge
- Institute of Medical Artificial Intelligence, Binzhou Medical University, Yantai, China
| | | | - Jiaxuan Xin
- Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, China
| | - Xiangqian Gong
- Department of Gastrointestinal Surgery, Yuhuangding Hospital, Yantai, China
| | - Xuhan Wang
- Department of Hemodialysis, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China
| | - Lijun Kong
- Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, China
| |
Collapse
|
2
|
Fritah H, Graciotti M, Lai-Lai Chiang C, Huguenin- Bergenat AL, Petremand R, Ahmed R, Guillaume P, Schmidt J, Stevenson BJ, Gfeller D, Harari A, Kandalaft LE. Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity. iScience 2023; 26:106288. [PMID: 36950115 PMCID: PMC10025090 DOI: 10.1016/j.isci.2023.106288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Revised: 01/22/2023] [Accepted: 02/21/2023] [Indexed: 03/03/2023] Open
Abstract
Antigen selection and prioritization represent crucial determinants of vaccines' efficacy. Here, we compare two personalized dendritic cell-based vaccination strategies using whole-tumor lysate or neoantigens. Data in mouse and in cancer patients demonstrate that peptide vaccines using neoantigens predicted on the sole basis of in silico peptide-major histocompatibility complex (MHC) binding affinity underperform relative to whole-tumor-lysate vaccines. In contrast, effective in vitro peptide-MHC binding affinity and peptide immunogenicity significantly improve the prioritization of tumor-rejecting neoepitopes and result in more efficacious vaccines.
Collapse
Affiliation(s)
- Hajer Fritah
- Ludwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland
- Agora Cancer Research Center, Lausanne, Switzerland
| | - Michele Graciotti
- Ludwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland
- Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland
- Agora Cancer Research Center, Lausanne, Switzerland
| | - Cheryl Lai-Lai Chiang
- Ludwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland
- Agora Cancer Research Center, Lausanne, Switzerland
| | - Anne-Laure Huguenin- Bergenat
- Ludwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland
- Agora Cancer Research Center, Lausanne, Switzerland
| | - Rémy Petremand
- Ludwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland
- Agora Cancer Research Center, Lausanne, Switzerland
| | - Ritaparna Ahmed
- Ludwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland
- Agora Cancer Research Center, Lausanne, Switzerland
| | - Philippe Guillaume
- Ludwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland
- Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland
| | - Julien Schmidt
- Ludwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland
- Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland
| | - Brian J. Stevenson
- Ludwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland
- Agora Cancer Research Center, Lausanne, Switzerland
- SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland
| | - David Gfeller
- Ludwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland
- Agora Cancer Research Center, Lausanne, Switzerland
- SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland
| | - Alexandre Harari
- Ludwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland
- Agora Cancer Research Center, Lausanne, Switzerland
- Corresponding author
| | - Lana E. Kandalaft
- Ludwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland
- Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland
- Agora Cancer Research Center, Lausanne, Switzerland
- Corresponding author
| |
Collapse
|
3
|
Yang F, Zhao L, Wei Z, Yang Y, Liu J, Li Y, Tian X, Liu X, Lü X, Sui J. A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects. THE JOURNAL OF IMMUNOLOGY 2020; 205:2156-2168. [PMID: 32887749 DOI: 10.4049/jimmunol.1901413] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/26/2019] [Accepted: 08/08/2020] [Indexed: 12/13/2022]
Abstract
The T cell immunoreceptor with Ig and ITIM domains (TIGIT) has been shown to exert inhibitory roles in antitumor immune responses. In this study, we report the development of a human mAb, T4, which recognizes both human and mouse TIGIT and blocks the interaction of TIGIT with its ligand CD155 in both species. The T4 Ab targets the segment connecting F and G strands of TIGIT's extracellular IgV domain, and we show in studies with mouse tumor models that the T4 Ab exerts strong antitumor activity and induces durable immune memory against various tumor types. Mechanistically, we demonstrate that the T4 Ab's antitumor effects are mediated via multiple immunological impacts, including a CD8+ T immune response and Fc-mediated effector functions, through NK cells that cause significant reduction in the frequency of intratumoral T regulatory cells (Tregs). Notably, this Treg reduction apparently activates additional antitumor CD8+ T cell responses, targeting tumor-shared Ags that are normally cryptic or suppressed by Tregs, thus conferring cross-tumor immune memory. Subsequent engineering for Fc variants of the T4 Ab with enhanced Fc-mediated effector functions yielded yet further improvements in antitumor efficacy. Thus, beyond demonstrating the T4 Ab as a promising candidate for the development of cancer immunotherapies, our study illustrates how the therapeutic efficacy of an anti-TIGIT Ab can be improved by enhancing Fc-mediated immune effector functions. Our insights about the multiple mechanisms of action of the T4 Ab and its Fc variants should help in developing new strategies that can realize the full clinical potential of anti-TIGIT Ab therapies.
Collapse
Affiliation(s)
- Fang Yang
- College of Biological Sciences, China Agricultural University, Beijing 100193, China.,National Institute of Biological Sciences, Beijing 102206, China
| | - Linlin Zhao
- National Institute of Biological Sciences, Beijing 102206, China.,Peking University-Tsinghua University-National Institute of Biological Sciences Joint Graduate Program, School of Life Sciences, Tsinghua University, Beijing 100084, China
| | - Zhizhong Wei
- National Institute of Biological Sciences, Beijing 102206, China.,Peking University-Tsinghua University-National Institute of Biological Sciences Joint Graduate Program, School of Life Sciences, Tsinghua University, Beijing 100084, China
| | - Yajing Yang
- National Institute of Biological Sciences, Beijing 102206, China.,Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China
| | - Juan Liu
- National Institute of Biological Sciences, Beijing 102206, China
| | - Yulu Li
- National Institute of Biological Sciences, Beijing 102206, China.,Peking University-Tsinghua University-National Institute of Biological Sciences Joint Graduate Program, College of Life Sciences, Peking University, Beijing 100871, China; and
| | - Xinxin Tian
- National Institute of Biological Sciences, Beijing 102206, China
| | - Ximing Liu
- National Institute of Biological Sciences, Beijing 102206, China
| | - Xueyuan Lü
- National Institute of Biological Sciences, Beijing 102206, China.,Peking University-Tsinghua University-National Institute of Biological Sciences Joint Graduate Program, School of Life Sciences, Tsinghua University, Beijing 100084, China
| | - Jianhua Sui
- National Institute of Biological Sciences, Beijing 102206, China; .,Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing 102206, China
| |
Collapse
|
4
|
Lee SE, Shin AR, Sohn HJ, Cho HI, Kim TG. T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity. Cancer Res Treat 2020; 52:747-763. [PMID: 32065848 PMCID: PMC7373873 DOI: 10.4143/crt.2019.721] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2019] [Accepted: 02/13/2020] [Indexed: 01/03/2023] Open
Abstract
PURPOSE Successful tumor eradication primarily depends on generation and maintenance of a large population of tumor-reactive CD8 T cells. Dendritic cells (DCs) are well-known potent antigen-presenting cells and have applied to clinics as potent antitumor therapeutic agents. However, high cost and difficulty in obtaining sufficient amounts for clinical use are the crucial drawbacks of DC-based vaccines. Here, we aimed to develop T cell-based vaccine capable of eliciting potent antitumor therapeutic effects by providing effective costimulatory signals. Materials and Methods Antigenic peptide-loaded T cells transfected with retrovirus encoding costimulatory ligands CD70, CD80, OX40L, or 4-1BBL were assessed for antigen-specific CD8 T-cell responses and evaluated antitumor effects along with immunization of a mixture of synthetic peptides, poly-IC and anti-CD40 antibodies (TriVax). RESULTS T cells expressing CD70 (CD70-T) exhibited similar level of stimulatory functionality and therapeutic efficacy as DCs. Moreover, CD70-T prime followed by TriVax booster heterologous vaccination elicited therapeutic antitumor effect against B16 melanoma where mediated by CD8 T cells but not CD4 T cells or natural killer cells. The combination with programmed death-ligand 1 blockade led to potent therapeutic efficacy which exhibited increased tumor-infiltrating CD8 T cells. CD70-T pulsed with multi-antigenic peptide generated multiple antigen-specific polyvalent CD8 T cells that were capable of inhibiting tumor growth effectively. Moreover, CD70-T vaccination resulted in higher expansion and migration of adoptively transferred T cells into tumor sites and elicits enhanced therapeutic effects with peptide-based booster immu-nization. CONCLUSION These results imply that T cells endowed with CD70 enable the design of effective vaccination strategies against solid cancer, which may overcome current limitations of DC-based vaccines.
Collapse
Affiliation(s)
- Sang-Eun Lee
- Department of Microbiology and Immunology, College of Medicine, The Catholic University of Korea, Seoul, Korea
| | - A-Ri Shin
- Department of Microbiology and Immunology, College of Medicine, The Catholic University of Korea, Seoul, Korea
| | - Hyun-Jung Sohn
- Translational and Clinical Division, ViGenCell Inc., Seoul, Korea
| | - Hyun-Il Cho
- Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul, Korea
| | - Tai-Gyu Kim
- Department of Microbiology and Immunology, College of Medicine, The Catholic University of Korea, Seoul, Korea.,Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul, Korea
| |
Collapse
|
5
|
Zhang H, Wang P, Wang X, Shi L, Fan Z, Zhang G, Yang D, Bahavar CF, Zhou F, Chen WR, Wang X. Antitumor Effects of DC Vaccine With ALA-PDT-Induced Immunogenic Apoptotic Cells for Skin Squamous Cell Carcinoma in Mice. Technol Cancer Res Treat 2018; 17:1533033818785275. [PMID: 30025490 PMCID: PMC6053869 DOI: 10.1177/1533033818785275] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Targeted immunotherapy using dendritic cell vaccine has been employed for the treatment
of solid tumors. Topical 5-aminolevulinic acid-mediated photodynamic therapy, an
established approach for topical cancers, can induce an effective antitumor immune
response. We have previously shown that 5-aminolevulinic acid-mediated photodynamic
therapy–induced tumor lysates could considerably enhance antigen-presenting capacity of
ex vivo-generated dendritic cells. The current study further
demonstrates that 5-aminolevulinic acid-mediated photodynamic therapy dendritic cell
vaccine can induce immune responses against cancers. Dendritic cells pulsed by
photodynamic therapy–treated skin squamous cell carcinoma cells inhibited squamous cell
carcinoma to a greater extent than tumor lysates treated by photodynamic therapy alone or
dendritic cells pulsed by freeze–thawed treated tumor cells. Immunohistochemistry showed
that photodynamic therapy dendritic cell vaccine could increase the activity of
CD4+ and CD8+ T cells in the tumor implantation sites. Flow
cytometry assays showed that CD4+ and CD8+ T cells in the spleens of
photodynamic therapy dendritic cell vaccine immunized mice increased significantly.
Furthermore, we observed increased amounts of interleukin 12 and Interferon gamma (IFN-γ)
and decreased amounts of interleukin 10 in the splenocytes and peripheral blood of
photodynamic therapy dendritic cell vaccine immunized mice by enzyme linked immunosorbent
assay (ELISA). Taken together, our findings suggest that photodynamic therapy dendritic
cell vaccination is an effective prophylactic therapy for squamous cell carcinoma.
Collapse
Affiliation(s)
- Haiyan Zhang
- 1 Shanghai Skin Disease Hospital, Shanghai, China.,2 Institute of Photomedicine and Department of Phototherapy at Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China
| | - Peiru Wang
- 1 Shanghai Skin Disease Hospital, Shanghai, China.,2 Institute of Photomedicine and Department of Phototherapy at Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China
| | - Xiaojie Wang
- 1 Shanghai Skin Disease Hospital, Shanghai, China.,2 Institute of Photomedicine and Department of Phototherapy at Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China
| | - Lei Shi
- 1 Shanghai Skin Disease Hospital, Shanghai, China.,2 Institute of Photomedicine and Department of Phototherapy at Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China
| | - Zhixia Fan
- 1 Shanghai Skin Disease Hospital, Shanghai, China.,2 Institute of Photomedicine and Department of Phototherapy at Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China
| | - Guolong Zhang
- 1 Shanghai Skin Disease Hospital, Shanghai, China.,2 Institute of Photomedicine and Department of Phototherapy at Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China
| | - Degang Yang
- 1 Shanghai Skin Disease Hospital, Shanghai, China.,2 Institute of Photomedicine and Department of Phototherapy at Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China
| | - Cody F Bahavar
- 3 Biophotonics Research Laboratory, Center for Interdisciplinary Biomedical Education and Research, University of Central Oklahoma, Edmond, OK, USA
| | - Feifan Zhou
- 3 Biophotonics Research Laboratory, Center for Interdisciplinary Biomedical Education and Research, University of Central Oklahoma, Edmond, OK, USA
| | - Wei R Chen
- 3 Biophotonics Research Laboratory, Center for Interdisciplinary Biomedical Education and Research, University of Central Oklahoma, Edmond, OK, USA
| | - Xiuli Wang
- 1 Shanghai Skin Disease Hospital, Shanghai, China.,2 Institute of Photomedicine and Department of Phototherapy at Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China
| |
Collapse
|
6
|
Choi CW, Jeong MH, Park YS, Son CH, Lee HR, Koh EK. Combination Treatment of Stereotactic Body Radiation Therapy and Immature Dendritic Cell Vaccination for Augmentation of Local and Systemic Effects. Cancer Res Treat 2018; 51:464-473. [PMID: 29879758 PMCID: PMC6473298 DOI: 10.4143/crt.2018.186] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2018] [Accepted: 06/01/2018] [Indexed: 12/31/2022] Open
Abstract
PURPOSE The purpose of this study was to investigate the efficacy of stereotactic body radiation therapy (SBRT) as a tumor-associated antigen (TAA) presentation method for dendritic cell (DC) sensitization and evaluate its effect in combination with immunotherapy using an intratumoral injection of immature DCs (iDCs). Methods and Materials CT-26 colon carcinoma cell was used as a cancer cell line. Annexin V staining and phagocytosis assays were performed to determine the appropriate radiation dose and incubation time to generate TAAs. BALB/c mice were used for in vivo experiments. Cancer cells were injected into the right legs and left flanks to generate primary and metastatic tumors, respectively. The mice were subjected to radiation therapy (RT) alone, intradermal injection of electroporated DCs alone, or RT in combination with iDC intratumoral injection (RT/iDC). Tumor growth measurement and survival rate analysis were performed. Enzyme-linked immunospot and cytotoxicity assays were performed to observe the effect of different treatments on the immune system. RESULTS Annexin V staining and phagocytosis assays showed that 15 Gy radiation dose and 48 hours of incubation was appropriate for subsequent experiments. Maximum DC sensitization and T-cell stimulation was observed with RT as compared to other TAA preparation methods. In vivo assays revealed statistically significant delay in the growth of both primary and metastatic tumors in the RT/iDC group. The overall survival rate was the highest in the RT/iDC group. CONCLUSION The combination of SBRT and iDC vaccination may enhance treatment effects. Clinical trials and further studies are warranted in the future.
Collapse
Affiliation(s)
- Chul Won Choi
- Department of Radiation Oncology, Dongnam Institute of Radiological & Medical Sciences, Busan, Korea
| | - Min Ho Jeong
- Department of Microbiology, Dong-A University College of Medicine, Busan, Korea
| | - You-Soo Park
- Department of Research Center, Dongnam Institute of Radiological & Medical Sciences, Busan, Korea
| | - Cheol-Hun Son
- Department of Research Center, Dongnam Institute of Radiological & Medical Sciences, Busan, Korea
| | - Hong-Rae Lee
- Department of Research Center, Dongnam Institute of Radiological & Medical Sciences, Busan, Korea
| | - Eun-Kyoung Koh
- Department of Research Center, Dongnam Institute of Radiological & Medical Sciences, Busan, Korea
| |
Collapse
|
7
|
Markov OV, Mironova NL, Vlassov VV, Zenkova MA. Antitumor Vaccines Based on Dendritic Cells: From Experiments using Animal Tumor Models to Clinical Trials. Acta Naturae 2017; 9:27-38. [PMID: 29104773 PMCID: PMC5662271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2017] [Indexed: 11/07/2022] Open
Abstract
The routine methods used to treat oncological diseases have a number of drawbacks, including non-specific action and severe side effects for patients. Furthermore, tumor diseases are associated with a suppression of the immune system that often leads to the inefficiency of standard treatment methods. The development of novel immunotherapeutic approaches having specific antitumor action and that activate the immune system is of crucial importance. Vaccines based on dendritic cells (DCs) loaded with tumor antigens ex vivo that can activate antitumor cytotoxic T-cell responses stand out among different antitumor immunotherapeutic approaches. This review is focused on analyzing different methods of DC-based vaccine preparation and current research in antitumor DC-based vaccines using animal tumor models and in clinical trials.
Collapse
Affiliation(s)
- O. V. Markov
- Institute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentieva Ave. 8, Novosibirsk, 630090 , Russia
| | - N. L. Mironova
- Institute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentieva Ave. 8, Novosibirsk, 630090 , Russia
| | - V. V. Vlassov
- Institute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentieva Ave. 8, Novosibirsk, 630090 , Russia
| | - M. A. Zenkova
- Institute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentieva Ave. 8, Novosibirsk, 630090 , Russia
| |
Collapse
|
8
|
Signorini L, Delbue S, Ferrante P, Bregni M. Review on the immunotherapy strategies against metastatic colorectal carcinoma. Immunotherapy 2017; 8:1245-61. [PMID: 27605072 DOI: 10.2217/imt-2016-0045] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Colorectal cancer (CRC) is one of the most common malignancies throughout the world and the leading cause of cancer-related mortality in Western countries. Recent progress in CRC treatment options, such as surgery, chemotherapy, radiotherapy and target therapy, has improved the prognosis, but advanced disease with recurrence or distant metastasis is usually incurable and has an unfavorable prognosis. The introduction of immunotherapy-associated strategies, both active and passive, to the treatment of CRC aims to overcome the limits of classical treatments. We review the state of the art for CRC with respect to different immunotherapeutic approaches, such as the use of cancer vaccines and/or adoptive cellular therapy, their most current advances and limitations and perspectives for further improvements.
Collapse
Affiliation(s)
- Lucia Signorini
- Department of Biomedical, Surgical & Dental Sciences, Via Pascal, 36, University of Milano, 20123 Milano, Italy
| | - Serena Delbue
- Department of Biomedical, Surgical & Dental Sciences, Via Pascal, 36, University of Milano, 20123 Milano, Italy
| | - Pasquale Ferrante
- Department of Biomedical, Surgical & Dental Sciences, Via Pascal, 36, University of Milano, 20123 Milano, Italy
| | - Marco Bregni
- Ospedale di Circolo di Busto Arsizio, Via A. Da Brescia, 1, 21052 Busto Arsizio VA, Italy
| |
Collapse
|
9
|
Markov OV, Mironova NL, Shmendel EV, Maslov MA, Zenkova MA. Systemic delivery of complexes of melanoma RNA with mannosylated liposomes activates highly efficient murine melanoma-specific cytotoxic T cells in vivo. Mol Biol 2017. [DOI: 10.1134/s0026893317010137] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
10
|
Liu KJ, Chao TY, Chang JY, Cheng AL, Ch'ang HJ, Kao WY, Wu YC, Yu WL, Chung TR, Whang-Peng J. A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment. J Biomed Sci 2016; 23:64. [PMID: 27558635 PMCID: PMC4997699 DOI: 10.1186/s12929-016-0279-7] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2016] [Accepted: 08/05/2016] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND To better evaluate and improve the efficacy of dendritic cell (DC)-based cancer immunotherapy, we conducted a clinical study of patients with advanced colorectal cancer using carcinoembryonic antigen (CEA)-pulsed DCs mixed with tetanus toxoid and subsequent interleukin-2 treatment. The tetanus toxoid in the vaccine preparation serves as an adjuvant and provides a non-tumor specific immune response to enhance vaccine efficacy. The aims of this study were to (1) evaluate the toxicity of this treatment, (2) observe the clinical responses of vaccinated patients, and (3) investigate the immune responses of patients against CEA before and after treatment. METHODS Twelve patients were recruited and treated in this phase I clinical study. These patients all had metastatic colorectal cancer and failed standard chemotherapy. We first subcutaneously immunized patients with metastatic colorectal cancer with 1 × 10(6) CEA-pulsed DCs mixed with tetanus toxoid as an adjuvant. Patients received 3 successive injections with 1 × 10(6) CEA-pulsed DCs alone. Low-dose interleukin-2 was administered subcutaneously following the final DC vaccination to boost the growth of T cells. Patients were evaluated for adverse event and clinical status. Blood samples collected before, during, and after treatment were analyzed for T cell proliferation responses against CEA. RESULTS No severe treatment-related side effects or toxicity was observed in patients who received the regular 4 DC vaccine injections. Two patients had stable disease and 10 patients showed disease progression. A statistically significant increase in proliferation against CEA by T cells collected after vaccination was observed in 2 of 9 patients. CONCLUSIONS The results of this study indicate that it is feasible and safe to treat colorectal cancer patients using this protocol. An increase in the anti-CEA immune response and a clinical benefit was observed in a small fraction of patients. This treatment protocol should be further evaluated in additional colorectal cancer patients with modifications to enhance T cell responses. TRIAL REGISTRATION ClinicalTrials.gov (identifier NCT00154713 ), September 8, 2005.
Collapse
Affiliation(s)
- Ko-Jiunn Liu
- National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan. .,Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University, Tainan, Taiwan. .,School of Medical Laboratory Science and Biotechnology, Taipei Medical University, Taipei, Taiwan.
| | - Tsu-Yi Chao
- Division of Hematology/Oncology, Tri-Service General Hospital, Taipei, Taiwan.,Present Address: Department of Hematology/Oncology, Taipei Medical University Shuang Ho Hospital, Taipei, Taiwan
| | - Jang-Yang Chang
- National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.,Present Address: Division of Hematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - Ann-Lii Cheng
- Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
| | - Hui-Ju Ch'ang
- National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
| | - Woei-Yau Kao
- Division of Hematology/Oncology, Tri-Service General Hospital, Taipei, Taiwan.,Present Address: Division of Hematology-Oncology, Department of Medicine, Taipei Tzu Chi Hospital, Taipei, Taiwan
| | - Yu-Chen Wu
- National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
| | - Wei-Lan Yu
- National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
| | - Tsai-Rong Chung
- National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
| | - Jacqueline Whang-Peng
- National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan. .,Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. .,Present Address: Comprehensive Cancer Center, Taipei Medical University, Taipei, Taiwan.
| |
Collapse
|
11
|
Liu Y, Wang YR, Ding GH, Yang TS, Yao L, Hua J, He ZG, Qian MP. JAK2 inhibitor combined with DC-activated AFP-specific T-cells enhances antitumor function in a Fas/FasL signal-independent pathway. Onco Targets Ther 2016; 9:4425-33. [PMID: 27499636 PMCID: PMC4959582 DOI: 10.2147/ott.s97941] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Objective Combination therapy for cancer is more effective than using only standard chemo- or radiotherapy. Our previous results showed that dendritic cell-activated α-fetoprotein (AFP)-specific T-cells inhibit tumor in vitro and in vivo. In this study, we focused on antitumor function of CD8+ T-cells combined with or without JAK2 inhibitor. Methods Proliferation and cell cycle were analyzed by CCK-8 and flow cytometry. Western blot was used to analyze the expression level of related protein and signaling pathway. Results We demonstrated reduced viability and induction of apoptosis of tumor cells with combination treatment. Intriguingly, cell cycle was blocked at the G1 phase by using AFP-specific CD8+ T-cells combined with JAK2 inhibitor (AG490). Furthermore, an enhanced expression of BAX but no influence on Fas/FasL was detected from the tumor cells. Conclusion These results indicate a Fas/FasL-independent pathway for cellular apoptosis in cancer therapies with the treatment of AFP-specific CD8+ T-cells combined with JAK2 inhibitor.
Collapse
Affiliation(s)
- Yang Liu
- Department of Hepatobiliary Surgery, Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China
| | - Yue-Ru Wang
- Department of Infection, Shanghai First People's Hospital Affiliated to Jiaotong University, Shanghai, People's Republic of China
| | - Guang-Hui Ding
- Department of Hepatobiliary Surgery, Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China
| | - Ting-Song Yang
- Department of Hepatobiliary Surgery, Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China
| | - Le Yao
- Department of Hepatobiliary Surgery, Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China
| | - Jie Hua
- Department of Hepatobiliary Surgery, Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China
| | - Zhi-Gang He
- Department of Hepatobiliary Surgery, Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China
| | - Ming-Ping Qian
- Department of Hepatobiliary Surgery, Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China
| |
Collapse
|
12
|
Rahmanian N, Bozorgmehr M, Torabi M, Akbari A, Zarnani AH. Cell separation: Potentials and pitfalls. Prep Biochem Biotechnol 2016; 47:38-51. [PMID: 27045194 DOI: 10.1080/10826068.2016.1163579] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Cell separation techniques play an indispensable part in numerous basic biological studies and even clinical settings. Although various cell isolation methods with diverse applications have been devised so far, not all of them have been able to gain widespread popularity among researchers and clinicians. There is not a single method known to be advantageous over all cell isolation techniques, and in fact, it is the researcher's aim in performing a study that determines the most suitable method. A perfect method for one study might not be necessarily a proper choice for another and likewise, expensive and complex isolation methods might not always be the best choices. There are several criteria such as cell purity, viability, activation status, and frequency that need to be given serious thought before selecting an isolation technique. Moreover, time and cost are two of the key elements that should be taken into consideration before implementing a project. Hence, here we provide a succinct description of six more popular cell separation methods with respect to their principles, advantages, and disadvantages as well as their most common applications. We further provide several key features of each technique so that it helps the researchers to take the first step toward opting for the best method that fits well into their projects.
Collapse
Affiliation(s)
- Narges Rahmanian
- a Department of Molecular Medicine, School of Advanced Technologies in Medicine , Tehran University of Medical Sciences , Tehran , Iran
| | - Mohmood Bozorgmehr
- b Oncopathology Research Center , Iran University of Medical Sciences , Tehran , Iran
| | - Monir Torabi
- c Department of Pathology, Shariati Hospital , Tehran University of Medical Sciences , Tehran , Iran
| | - Abolfazl Akbari
- d Colorectal Research Center , Iran University of Medical Sciences , Tehran , Iran
| | - Amir-Hassan Zarnani
- e Department of Immunology , School of Public Health, Tehran University of Medical Sciences , Tehran , Iran.,f Immunology Research Center , Iran University of Medical Sciences , Tehran , Iran
| |
Collapse
|